James E Deerfield Mgmt L.P.... Net Worth

The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least 36.4 百万$ dollars as of 28 September 2015. James P owns over 1,828,529 units of Antares Pharma Inc stock worth over 29,899,658$ and over the last 9 years James sold ATRS stock worth over 6,546,134$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James P ATRS stock SEC Form 4 insiders trading

James has made over 2 trades of the Antares Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James sold 1,828,529 units of ATRS stock worth 3,273,067$ on 28 September 2015.

The largest trade James's ever made was selling 1,828,529 units of Antares Pharma Inc stock on 28 September 2015 worth over 3,273,067$. On average, James trades about 1,828,529 units every 0 days since 2015. As of 28 September 2015 James still owns at least 5,348,776 units of Antares Pharma Inc stock.

You can see the complete history of James P stock trades at the bottom of the page.

Insiders trading at Antares Pharma Inc

Over the last 12 years, insiders at Antares Pharma Inc have traded over 29,755,747$ worth of Antares Pharma Inc stock and bought 910,400 units worth 1,278,090$ . The most active insiders traders include James E Deerfield Mgmt L.P....、James E Deerfield Mgmt L.P....、Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of 751,296$. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth 429,000$.

What does Antares Pharma Inc do?

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Complete history of James P stock trades at Antares Pharma Inc

Antares Pharma Inc executives and stock owners

Antares Pharma Inc executives and other stock owners filed with the SEC include:

• Robert F. Apple,
  CEO, Pres & Director
• Fred M. Powell,
  Exec. VP & CFO
• Peter J. Graham,
  Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Greg Defilippis,
  Sr. VP of Device Bus. & Alliances
• Dr. Jonathan S. Jaffe,
  Interim EVP, Pharmaceutical R&D and Chief Medical Officer
• Dr. Peter Sadowski,
  Sr. VP of Technology Portfolio & Intellectual Property
• Edward Tykot,
  Sr. VP of Corp. Bus. Devel.
• Tram Bui,
  VP of Corp. Communications & Investor Relations
• Keith Muckenhirn,
  Principal Accounting Officer, VP of Fin. & Corp. Controller
• Patrick Madsen,
  Sr. VP of Operations
• Anton Gueth,
  Director
• Robert P Jr Roche,
  Director
• Thomas J Garrity,
  Director
• Fred M Powell,
  Executive Vice President & CFO
• Leonard S Jacob,
  Director
• Marvin Samson,
  Director
• James E Fickenscher,
  Senior Vice President & CFO
• James E Deerfield Mgmt L.P....,
  
• Jacques Gonella,
  Director
• Peter J Graham,
  See Remarks
• James Patrick Tursi,
  EVP, Chief Medical Officer
• Peter Greenleaf,
  Director
• Karen L. Smith,
  Director
• James E Deerfield Mgmt L.P....,
  
• Kaushik J Dave,
  Executive Vice President
• Jennifer Evans Stacey,
  SVP, General Counsel & Secty
• James E Deerfield Mgmt L.P....,
  
• Paul K Wotton,
  President and CEO
• Eamonn P Hobbs,
  Director
• Peter C Richardson,
  See Remarks
• Carmen B Volkart,
  Director
• Robert F Apple,
  President and CEO